Response to Thrombotic Microangiopathy: COVID-19 or Hydroxychloroquine?

We thank Dr Hasbal for the concern expressed (1) regarding hydroxychloroquine (HCQ) as the cause of the TMA in our published case titled “Thrombotic microangiopathy (TMA) in a patient with COVID-19”(2). An immune mediated thrombotic microangiopathy usually requires ongoing exposure to the drug. In our case, the patient mentioned was on HCQ for a duration of 5 days. The initial 2 doses were prior to the admission and the drug was continued during the initial 3 days of hospitalization. The findings of hemolysis and TMA developed on day 17 of the admission which was 2 weeks after the drug had been discontinued.

Source: Kidney International - September 20, 2020 Category: Urology & Nephrology Authors: Rimda Wanchoo, Maria Louise Barilla-LaBarca, Kenar D. Jhaveri Tags: letters to the editor Source Type: research